ClinicalTrials.gg
Not yet recruitingNCT07526662Updated Apr 13, 2026

Maternal-Fetal Heart Sound/Electrocardiogram Monitoring and Cardiac Risk Early Warning

An observational study in Pregnancy-Associated Heart Disease, Fetal Congenital Heart Disease and Autoimmune-Related Fetal Heart Block, sponsored by Yihua He,MD. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Yihua He,MD · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

This is a prospective observational cohort study conducted at Beijing Anzhen Hospital. The study aims to establish reference ranges of heart sound and electrocardiogram (ECG) parameters for both mothers and fetuses. It seeks to develop early warning models for maternal adverse cardiac events, fetal congenital heart disease progression, and autoimmune-related fetal heart block, thereby building a comprehensive maternal-fetal integrated risk stratification system.

Read the detailed description

Perinatal cardiovascular health poses significant threats to maternal and fetal safety. Pregnancy-associated heart disease remains the leading cause of non-obstetric maternal mortality in China. While conventional assessments rely on static and intermittent monitoring, dynamic changes in cardiac function during pregnancy often go undetected, leading to missed opportunities for early intervention.

Fetal congenital heart disease (CHD) and autoimmune-related fetal complete heart block (CHB) are major causes of adverse perinatal outcomes. Current diagnostic methods, primarily relying on fetal echocardiography, struggle to detect early electrophysiological abnormalities, resulting in delayed warning times.

This study integrates non-invasive wearable technology to dynamically collect maternal-fetal heart sound and ECG signals. It aims to establish normal reference standards, screen sensitive early warning indicators, construct predictive models for perinatal adverse events, and finally develop a clinical risk stratification workflow. Signal acquisition was initiated at the following gestational ages: fECG from approximately 12 weeks of gestation, fPCG from approximately 16 weeks of gestation, and maternal signals (mECG and mPCG) from the time of enrollment. All signals were acquired serially until delivery.

02

Conditions studied

  • Pregnancy-Associated Heart Disease
  • Fetal Congenital Heart Disease
  • Autoimmune-Related Fetal Heart Block
  • Perinatal Adverse Events

Browse trials for

03

In context

Heart Block

39 studies on the registry are indexed under Heart Block; 12 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 765 across 15 observational studies indexed under Heart Block.

Browse Heart Block studies →

Lead sponsor

This is the only study on the registry with Yihua He,MD as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This study population consists of pregnant women aged 18-45 years with singleton pregnancies, including those with pregnancy-associated heart disease, anti-Ro/SSA antibody positivity, and healthy controls, and their fetuses, enrolled at Beijing Anzhen Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pregnant women aged 18 to 45 years with singleton pregnancy;
  2. For maternal groups: diagnosed with heart disease (congenital, valvular, or cardiomyopathy) or healthy without cardiac disease;
  3. For fetal groups: diagnosed with congenital heart disease, anti-Ro/SSA antibody positive status, or normal cardiac structure;
  4. Able to cooperate with non-invasive monitoring and follow-up procedures;
  5. Voluntary written provided prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Multiple pregnancy;
  2. Severe skin disease or thoracic deformity preventing placement of monitoring sensors;
  3. History of , severe hepatic or renal dysfunction;
  4. Inability to complete follow-up visits or monitoring;
  5. to non-invasive monitoring procedures.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pregnant Women with Heart Disease

    This group includes pregnant women with pre-existing cardiac conditions (e.g., congenital heart disease, valvular heart disease, cardiomyopathy, arrhythmia). They undergo serial non-invasive monitoring of cardiac function (via heart sound and ECG) throughout pregnancy and postpartum to identify early signs of decompensation.

  • Healthy Pregnant Women (Control)

    This control group includes pregnant women without known cardiac disease, matched for age and gestational age. They undergo the same non-invasive cardiac monitoring protocol as the study group to establish baseline reference values.

  • Fetuses with Congenital Heart Disease (CHD)

    This group includes fetuses diagnosed with congenital heart disease via prenatal ultrasound. Serial non-invasive monitoring (via fetal ECG and heart sound) is performed to track disease progression and identify early signs of hemodynamic compromise.

  • Fetuses of Anti-Ro/SSA Positive Mothers

    This high-risk group includes fetuses of mothers with anti-Ro/SSA antibodies, who are at increased risk of developing congenital heart block. Serial fetal ECG monitoring is performed from 16 weeks of gestation to detect early signs of atrioventricular conduction abnormalities.

  • Healthy Singleton Fetuses (Control)

    This control group includes fetuses with normal cardiac anatomy on prenatal ultrasound, matched for gestational age. They undergo the same non-invasive monitoring protocol as the study groups to establish normal reference values for fetal cardiac parameters.

06

What researchers measure

Primary outcomes

  1. Maternal Major Adverse Cardiac Events (MACE)

    Composite endpoint including cardiac death, cardiac arrest, heart failure requiring hospitalization, sustained ventricular arrhythmia, stroke, myocardial infarction, and aortic dissection occurring during the study period.

    Time frame: From study enrollment to 6 weeks postpartum

  2. Fetal Congenital Heart Disease (CHD) Progression

    Composite endpoint including fetal hemodynamic deterioration, right ventricular dysfunction, hydrops fetalis, or delivery before 37 weeks due to worsening CHD, as assessed by serial fetal echocardiography.

    Time frame: From first signal acquisition (fECG at 12 weeks, fPCG at 16 weeks) until delivery or withdrawal, with serial fetal echocardiography throughout; assessed up to 28 weeks.

  3. Autoimmune-Related Fetal Complete Heart Block (CHB)

    Development of second-degree or third-degree atrioventricular block in fetuses of anti-SSA/SSB antibody-positive mothers, detected by serial fetal ECG monitoring.

    Time frame: From 16 weeks of gestation to delivery

Secondary outcomes

  1. Emergency Cesarean Section Due to Cardiac Indications

    Unplanned cesarean delivery performed due to maternal cardiac decompensation, refractory arrhythmia, or fetal distress related to cardiac disease.

    Time frame: From study enrollment until the date of delivery or study withdrawal, whichever came first, assessed up to approximately 34 weeks.

  2. Preterm Birth

    Delivery occurring before 37 weeks of gestation, including spontaneous preterm labor and medically indicated preterm delivery.

    Time frame: At delivery

  3. Low Birth Weight

    Birth weight less than 2500 grams, as measured at delivery.

    Time frame: At delivery

  4. Multimodal cardiac signal acquisition feasibility and fetal cardiac acoustic feature characterization

    Including: (1) four-channel simultaneous signal acquisition success rate; (2) signal quality metrics for mECG, fECG, mPCG, and fPCG; (3) quantitative differences in fPCG acoustic features between CHD-affected and normal fetuses, as assessed by algorithm analysis.

    Time frame: From study enrollment until delivery or study withdrawal, whichever came first, assessed up to approximately 28 weeks

07

Study locations

1 site
  • Beijing An Hospital, Capital Medical University
    Beijing, 100011, China
08

References and documents

Individual participant data

Plan to share: No — The individual participant data (IPD) from this study will not be shared publicly due to patient privacy regulations, institutional review board requirements, and the sensitive nature of maternal and fetal health data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for May 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2026
First posted
Apr 13, 2026
StartEst.
May 2026
Primary completionEst.
May 2028
CompletionEst.
May 2028
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07526662
Lead sponsor
Yihua He,MD
Responsible party
Yihua He,MD (Chief Physician, Director of Echocardiography Medical Center, Director of Beijing Key Laboratory of Maternal-Fetus Medicine in Fetal Heart Disease, Professor, Beijing Anzhen Hospital) — Sponsor-investigator
First posted
Apr 13, 2026
Start date
May 2026 (estimated)
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Apr 13, 2026

Study contacts

yihua he
Contact
yihuaheecho@163.com
+86 18910778673

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion